A team of scientists has found that cyclocreatine, a dietary supplement, may block an avenue for growth for HER2-positive breast cancers. The findings, outlined in a study published Aug. 30 in Cell Metabolism, helped develop a treatment method that reduced cancer growth without toxicity in mice.